Skip to main content
. 2017 Sep 22;38(5):2705–2716. doi: 10.3892/or.2017.5989

Figure 4.

Figure 4.

Analysis of the molecular mechanism of PF-3758309 treatment in neuroblastoma cells. (A) Western blot analysis of PARP and PAK4 expression after 24 h treatment with serial concentrations of PF-3758309 in lysates from SH-SY5Y and IMR-32 cells. (B) Western blot analysis of PARP and PAK4 expression in PAK4-knockout SH-SY5Y cells. (C) Gene expression clustering of 370 key apoptosis-related genes in the 5 µM PF-3758309-treated SH-SY5Y cells compared to DMSO-treated cells. (D) Differentially expressed mRNAs upregulated in the SH-SY5Y cells treated with 5 µM PF-3758309. (E) Differentially expressed mRNAs downregulated in SH-SY5Y cells treated with 5 µM PF-3758309. (F) Western blot analysis of PAK4, AATF, Bcl-2, Bax, BAD, CDKN1A and BAK1 expression in SH-SY5Y cells after 24 h of PF-3758309 treatment. All data are representative of 3 independent experiments with n=3–6/group and are means ± SEM.